Abstract

Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication.

This guidance updates and replaces:

  • infliximab for subacute manifestations of ulcerative colitis (TA140)
  • adalimumab for the treatment of severe ulcerative colitis (terminated appraisal, TA262)
  • moderately to severely active ulcerative colitis: adalimumab (NICE advice ESNM6).

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.